CAM
PBYI icon

ClariVest Asset Management’s Puma Biotechnology PBYI Stock Holding History

ClariVest Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,844
Closed -$635K – 749
2018
Q3 		$635K Sell
13,844
-309
-2% -$14.9K 0.01% 475
2018
Q2 		$838K Buy
14,153
+2,921
+26% +$169K 0.01% 465
2018
Q1 		$764K Buy
11,232
+100
+0.9% +$7.49K 0.01% 461
2017
Q4 		$1.1M Buy
+11,132
New +$1.25M 0.02% 415
2015
Q3 		– Sell
-5,971
Closed -$696K – 639
2015
Q2 		$696K Sell
5,971
-9
-0.2% -$1.63K 0.02% 314
2015
Q1 		$1.41M Sell
5,980
-94
-2% -$20.1K 0.04% 252
2014
Q4 		$1.15M Sell
6,074
-512
-8% -$114K 0.04% 217
2014
Q3 		$1.57M Buy
+6,586
New +$1.35M 0.06% 197

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

ClariVest Asset Management's PBYI Position: Q4 2018 in Review

ClariVest Asset Management sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 13,844 shares — an estimated $635K sold.

ClariVest Asset Management first reported a position in PBYI in Q3 2014 and held it in 8 quarters. The position peaked at $1.57M in Q3 2014. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

  • ClariVest Asset Management reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
  • ClariVest Asset Management sold 13,844 Puma Biotechnology shares in Q4 2018, an estimated $635K.
  • ClariVest Asset Management first reported a position in Puma Biotechnology in Q3 2014 and held it in 8 quarters.
  • ClariVest Asset Management's Puma Biotechnology position peaked at $1.57M in Q3 2014.
  • 141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on ClariVest Asset Management's 13F filing for Q4 2018, filed 5 Feb 2019.